After the Securities and Exchange Commission launched an informal inquiry into Dendreon last summer, many thought its cancer drug Provenge would never hit the market. But European authorities have added a new twist to Dendreon's saga.
Link to Article
Forbes.com
|
|
||||
|
This Month
Month Archive
RSS Newsfeeds
Main Page RSS
|
Tuesday, January 15
Dendreon Scores European Patent Approval
by
Alex Hsieh on behalf of Professor Henry Wang
on Tue 15 Jan 2008 11:17 PM EST
SAFC boosts biologics
by
Alex Hsieh on behalf of Professor Henry Wang
on Tue 15 Jan 2008 11:14 PM EST
15/01/2008 - SAFC is still on its expansion drive, with yet another multi-million dollar investment announced this week, this time at the company's niche biologics plant in Carlsbad, California.
Link to Article in-pharmatechnologist.com
What's Next For Vytorin?
by
Alex Hsieh on behalf of Professor Henry Wang
on Tue 15 Jan 2008 11:12 PM EST
When Merck and Schering-Plough revealed Monday that the active ingredient in their top-selling cholesterol meds Zetia and Vytorin had flunked a clinical trial measuring its effect on artery plaque, they opened themselves up to a barrage of attacks.
Link to Article Forbes.com
Study Casts Doubt on Cholesterol Drug
by
Alex Hsieh on behalf of Professor Henry Wang
on Tue 15 Jan 2008 11:09 PM EST
A clinical trial has shown that the combination cholesterol drug Vytorin is no more effective than a high dose of one of its components available generically, Vytorin's makers said Monday.
Link to Article ABC News
FDA approves genetic breast cancer test
by
Alex Hsieh on behalf of Professor Henry Wang
on Tue 15 Jan 2008 11:07 PM EST
U.S. regulators cleared a new genetic test on Monday that helps predict tumor recurrence and long-term survival in breast cancer patients with higher risk of the cancer returning.
Link to Article MSNBC.com
FDA Aims To Establish Overseas Staff Posts, Starting In China
by
Alex Hsieh on behalf of Professor Henry Wang
on Tue 15 Jan 2008 10:05 PM EST
FDA is considering posting staff overseas to perform inspections and foster relationships with foreign government counterparts and industry.
Link to Article MedicalDevicesToday.com
Novo drops inhaled insulin plans in post-Exubera fallout
by
Lyle
on Tue 15 Jan 2008 08:30 PM EST
15/01/2008 - Mere months after Pfizer's high profile exit from the inhaled insulin market in the wake of Exubera's much publicised market failure, Novo Nordisk announced late last night that it, too, has decided to halt development of its inhaled insulin product.
Link to Article In-Pharmatechnologist.com
Study Reveals Doubt on Drug for Cholesterol
by
Lyle
on Tue 15 Jan 2008 08:29 PM EST
A clinical trial of Zetia, a widely used cholesterol drug, has raised questions about its effectiveness and the behavior of pharmaceutical companies that conducted the study.
Link to Article NYTimes.com
Funding shot for cell-based vaccines
by
Lyle
on Tue 15 Jan 2008 08:27 PM EST
14/01/2008 - A major grant has been awarded to a UK consortium working to develop predictive manufacturing tools for cell-based cancer vaccines.
Link to Article In-Pharmatechnologist.com
Team Creates Rat Heart Using Cells of Baby Rats
by
Lyle
on Tue 15 Jan 2008 08:26 PM EST
The accomplishment gave a significant boost to medicine’s dream of growing human organs to replace damaged ones.
Link to Article NYTimes.com
Drug Approved. Is Disease Real?
by
Lyle
on Tue 15 Jan 2008 08:25 PM EST
The first drug to treat fibromyalgia has been approved, but some dispute the very existence of the condition.
Link to Article NYTimes.com
A Drug to End Drug Addiction
by
Lyle
on Tue 15 Jan 2008 08:24 PM EST
GEN News Highlights - 1/11/08
by
Lyle
on Tue 15 Jan 2008 08:20 PM EST
Link to All Articles
Jan 09 2008, 11:28 AM EST PerkinElmer Obtains Finnish Site for Genetic Screening Services This is the company's second facility in the area, which will also be used for R&D. Full Story Jan 09 2008, 12:00 PM EST Investigators Uncover Novel Mechanism in Huntington's Disease Prior to creating destructive aggregates, htt induces abnormally high transmission of neurotransmitters, according to Neuron paper. Full Story Jan 09 2008, 11:32 AM EST BioTime Licenses Human Embryonic Stem Cell Technology from WARF Agreement enhances the firm's ability to launch three products in the next two years that will facilitate work in this field. Full Story Jan 09 2008, 11:37 AM EST Celtic Pharma and Inspiration Ink $35M Hemophilia B Deal Celtic will take an equity stake and provide development funding for Inspiration's lead candidate. Full Story Jan 08 2008, 12:24 PM EST Researchers Identify 480 Genes Involved in Cell Division Computational tools were used, and 100 of these genes were linked to cancer, according to PNAS paper. Full Story Jan 08 2008, 12:26 PM EST ATMI Acquires LevTech for $27M to Fortify Its Position as a Disposable Technology Supplier LevTech will be combined with ATMI's existing LifeSciences segment. Full Story Jan 07 2008, 12:25 PM EST Pfizer and Tacere Enter HCV Deal Worth over $145M Pfizer will back development and will be able to commercialize Tacere's preclinical candidate. Full Story Jan 04 2008, 11:10 AM EST Biodel Plans Manufacturing Facility for Injectable Insulin Product Plant will cost under $15 million and will be ready in 2009. Full Story Jan 04 2008, 11:13 AM EST Osiris and Genzyme Awarded DoD Contract for Acute Radiation Syndrome Treatment Valued at $224.7M Firms will receive development funding, and upon approval, 20,000 doses will be sold for a total of $200 million. Full Story Jan 04 2008, 11:11 AM EST WuXi PharmaTech to Acquire AppTec Laboratory Services for $151M Transactions will strengthen company's U.S. presence. Full Story GenEngNews.com
Study Finds Possible Targets for H.I.V. Drugs
by
Lyle
on Tue 15 Jan 2008 08:17 PM EST
Researchers at Harvard Medical School have identified 273 proteins that the AIDS virus needs to survive in human cells, which could lead to new strategies for combating the disease.
Link to Article NYTimes.com |
Search
Links
|
||